Clinical Trial Update: A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy, safety, and tolerability of monthly long-acting GA Depot IM injection in relapsing-remitting multiple sclerosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GA Depot (GA Depot)

Snippet

Sponsor: Mapi Pharma Ltd. | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED